Haya Therapeutics

Haya Therapeutics develops ribonucleic acid therapies that target the regulatory genome to treat serious health conditions. The company’s platform focuses on creating cell-state-modifying therapeutics by decoding the function of long non-coding RNAs. Its treatments are designed for cardiovascular disease, cancer and other rare or chronic conditions. Haya Therapeutics primarily serves the healthcare sector.